menu search

VERA / Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022

Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
BRISBANE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced that interim data from the Phase 2 trial of MAU868 versus placebo to treat BK Virus (BKV) in kidney transplant patients will be delivered in a late-breaking oral presentation at the American Transplant Congress (ATC) 2022 in Boston, Massachusetts. Read More
Posted: May 2 2022, 19:06
Author Name: GlobeNewsWire
Views: 110218

VERA News  

Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)

By Zacks Investment Research
October 18, 2023

Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)

The heavy selling pressure might have exhausted for Vera Therapeutics, Inc. (VERA) as it is technically in oversold territory now. In addition to this more_horizontal

Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)

By Zacks Investment Research
October 17, 2023

Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)

Vera Therapeutics, Inc. (VERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combi more_horizontal

Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround

By Zacks Investment Research
October 16, 2023

Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround

Vera Therapeutics, Inc. (VERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong ag more_horizontal

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

By GlobeNewsWire
October 13, 2023

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Informational poster for ORIGIN 3 Pivotal Phase 3 study evaluating atacicept in IgA Nephropathy (IgAN) Additional analysis of week 36 data from Phase more_horizontal

What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock

By Zacks Investment Research
August 15, 2023

What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock

Vera Therapeutics, Inc. (VERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This mi more_horizontal

Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target

By Seeking Alpha
July 4, 2023

Vera: New Kidney Data, May Be A Potential Next Big Pharma M&A Target

Vera Therapeutics revealed 36-week efficacy and safety findings of its Phase IIb ORIGIN clinical study of atacicept for IgAN at the 60th European Rena more_horizontal

Vera: Repurposed Molecule Program Does Not Impress

By Seeking Alpha
July 3, 2023

Vera: Repurposed Molecule Program Does Not Impress

Vera Therapeutics, Inc. is trying to develop an old molecule it licensed from Merck & Co., Inc. Trials conducted years earlier produced unimpressive r more_horizontal

Why Shares of Vera Therapeutics Jumped Tuesday

By The Motley Fool
June 20, 2023

Why Shares of Vera Therapeutics Jumped Tuesday

The company's lead therapy, Atacicept, is faring well in a phase 2b trial. Vera Therapeutics is already recruiting patients for a phase 3 trial for At more_horizontal


Search within

Pages Search Results: